UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, exercised 9,500 stock options and sold the resulting 9,500 shares of common stock via a 10b5-1 trading plan on August 24, 2026.

On August 24, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring 9,500 shares of common stock, and immediately sold those 9,500 shares in a series of open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The sales were executed in multiple tranches at weighted-average prices ranging from approximately $509.41 to $513.35 per share, generating total sale proceeds of roughly $4.82 million versus an aggregate exercise cost of about $1.29 million, implying a gain of roughly $3.5 million before taxes. Following these transactions, the reporting person, through various direct and indirect holdings (primarily family trusts and a small spouse-held position), reports ongoing beneficial ownership of several hundred thousand shares of United Therapeutics common stock, with the trust holdings involved in this transaction reported at 324,443 shares; using the prevailing sale-price range as a proxy, the value of these trust-held shares alone is approximately $166 million, and total family-related holdings are materially higher.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000127

Alert Tier

7